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Primary care
Predictors of normotension on withdrawal of
antihypertensive drugs in elderly patients: prospective study
in second Australian national blood pressure study cohort
Mark R Nelson, Chris M Reid, Henry Krum, Tui Muir, Philip Ryan, John J McNeil
Abstract
Objectives To identify simple long term predictors of
maintenance of normotension after withdrawal of
antihypertensive drugs in elderly patients in general
practice.
Design Prospective cohort study.
Setting 169 general practices in Victoria, Australia.
Participants 503 patients aged 65›84 with treated
hypertension who were withdrawn from all
antihypertensive drugs and remained drug free and
normotensive for an initial two week period; all were
followed for a further 12 months.
Main outcome measures Relative likelihood of
maintaining normotension 12 months after drug
withdrawal; relative likelihood of early return to
hypertension after drug withdrawal.
Results The likelihood of remaining normotensive at
12 months was greater among younger patients
(65›74 years), patients with lower “on›treatment”
systolic blood pressure, patients on single agent
treatment, and patients with a greater waist:hip ratio.
The likelihood of return to hypertension was greatest
for patients with higher “on›treatment” systolic blood
pressure.
Conclusions Age, blood pressure control, and the
number of antihypertensive drugs are important
factors in the clinical decision to withdraw drug
treatment. Because of consistent rates of return to
antihypertensive treatment, all patients from whom
such treatment is withdrawn should be monitored
indefinitely to detect a recurrence of hypertension.
Introduction
A systematic review of predictors of maintenance of
normotension after withdrawal of antihypertensive
drugs indicated that if treatment is withdrawn from
selected patients with mild to moderate hypertension
then approximately 42% of these patients are likely to
remain normotensive after 12 months.1 Predictors of
success for maintenance of normotension have been
identified in these studies and indicate that patients
with long term, well controlled, mild hypertension on
single agent antihypertensive treatment are optimal
candidates for a trial of withdrawal of antihypertensive
drugs, especially if they are also willing to undertake
appropriate lifestyle changes.
We report the experience of withdrawal of
antihypertensive drugs in 503 patients aged 65›84
years in a cohort study conducted in an Australian
general practice setting and identify characteristics of
patients that predict successful maintenance of
normotension over a 12 month period. The study was
novel in prospectively investigating predictors of
successful antihypertensive drug withdrawal for elderly
patients that are likely to be useful to a general
practitioner in routine clinical practice.
Methods
We used a prospective cohort design to investigate pre›
dictors of persistent normotension 12 months after
withdrawal of antihypertensive drug treatment. We
used participating general practitioners’ databases to
identify suitable participants—patients aged 65›84
years with a history of treated hypertension. We drew
participants from among patients volunteering for
inclusion in the second Australian national blood pres›
sure study. This was a large randomised controlled trial
comparing angiotensin converting enzyme inhibitor
and diuretic based antihypertensive treatment for
major cardiovascular outcomes and all cause mor›
tality.2 Patients taking antihypertensive drugs at screen›
ing were offered withdrawal of drugs as part of the
run›in phase. Pretreatment blood pressure could not
be identified for all participants, so hypertensive status
relied on self reporting. Patients who returned to
hypertension were eligible for enrolment in the second
Australian national blood pressure study.
Patients who agreed to participate had their previ›
ous antihypertensive drug treatment withdrawn gradu›
ally under the supervision of a research nurse. During
the drug withdrawal phase participants were seen
weekly for blood pressure monitoring until a
minimum of two weeks after cessation of all antihyper›
tensive drugs. Only those patients whose blood
pressure remained within the normotensive range at
the two week post›withdrawal visit entered the present
study. We defined “normotension” as a sitting systolic
blood pressure below 160 mm Hg and a diastolic pres›
sure below 90 mm Hg. These criteria are now historical
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the second Australian national blood pressure study in
early 1995. However, in previous studies the level of
defined hypertension did not alter the success of drug
withdrawal.1
Candidate predictors of maintenance of normo›
tension included body mass index, waist:hip ratio,
blood pressure (on›treatment diastolic and systolic),
heavy or higher weekend (binge) alcohol intake, recent
exercise (walking or other vigorous activity), number of
antihypertensive drugs taken, sex, and age. We selected
these potential predictors on the basis of previous
studies and ready availability to a general practitioner.
After a minimum of two visits to the nurse after
cessation of all antihypertensive drugs, participants
were followed up by their general practitioner.
Typically, general practitioners reviewed each partici›
pant 10 times during the subsequent 12 month period
(range 1›56 reviews) and recorded blood pressure on
four or five occasions (range 0›29 recordings). We
reviewed the clinical notes of all participants six and 12
months after withdrawal of treatment and extracted
data on blood pressure, drugs, and adverse cardiovas›
cular events. A research nurse measured participants’
sitting blood pressure with a standard sphygmoma›
nometer at a 12 month visit.
Twelve months after their entry into the study we
classified patients into three groups: (1) Remained off
antihypertensive treatment and were normotensive at
the 12 month visit (“maintain normotension”). (2) Met
study criteria for return to hypertension according to
measurement by the study nurse (seated systolic blood
pressure>160 mm Hg or diastolic blood pressure>90
mm Hg where systolic blood pressure >140 mm Hg)
or had restarted antihypertensive treatment because of
a blood pressure level that the general practitioner
considered to justify reinstitution of treatment at or
before the 12 month visit (“return to hypertension”).
We also analysed this group as “return to hypertension
early” ( < 70 days) and “return to hypertension late”
(>70 days). (3) Restarted antihypertensive treatment
for reasons unrelated to blood pressure or died before
classification—this group is referred to as “other.”
Statistical analysis
We assessed the relation between potential predictors
and normotensive status at 12 months by using Cox’s
proportional hazards regression in order to estimate
relative risks, using a constant follow up time of one
year with robust estimation of variance to account for
clustering within doctor.3 4 We used a multivariate
model to determine independent predictors, after
standardising continuous predictors to account for dif›
ferences in scale. We used SAS version 8.2 for all analy›
ses.
Results
The study population consisted of 503 participants, all
of whom had remained normotensive for at least two
weeks after withdrawal of all antihypertensive drug
treatment. All but five participants were followed
according to the protocol and reviewed 12 months
after study entry. At this time 181 (36%) were classified
as “maintain normotension,” 273 (54%) as “return to
hypertension,” and 49 (10%) as “other.” Four partici›
pants had died during the interim period, two from








early” (<70 days) (n=135)
“Return to hypertension
late” (>70 days) (n=138)
Sex:
Female 95 (52.5) 161 (59.0) 72 (53.3) 89 (64.5)
Male 86 (47.5) 112 (41.0) 63 (46.7) 49 (35.5)
Median (range) age (years) 70.0 (65.0›84.0) 71.0 (65.0›84.0) 72.0 (65.0›84.0) 71.0 (65.0›82.0)
Mean (SD) pretreatment blood pressure (mm Hg):
Systolic 169.8 (20.0) 169.4 (18.1) 171.6 (17.7) 167.5 (18.4)
Diastolic 93.7 (10.2) 94.5 (9.6) 94.6 (9.7) 94.5 (9.6)
Mean (SD) on›treatment blood pressure (mm Hg):
Systolic 135.3 (13.0) 141.4 (13.6) 143.5 (13.4) 139.3 (13.5)
Diastolic 76.0 (8.9) 77.0 (7.8) 77.5 (7.9) 76.5 (7.8)
Mean arterial 95.7 (8.9) 98.4 (8.3) 99.5 (8.0) 97.4 (8.6)
Pulse pressure 59.3 (11.6) 64.4 (12.1) 66.0 (12.8) 62.9 (11.2)
Other cardiovascular disease risk factors:
Mean (SD) body mass index (kg/m2) 26.9 (3.4) 27.3 (4.1) 27.0 (4.0) 27.5 (4.2)
Mean (SD) waist:hip ratio 0.9 (0.1) 0.9 (0.1) 0.9 (0.1) 0.9 (0.1)
Raised cholesterol concentration 102 (56.4) 118 (43.2) 49 (36.3) 69 (50.0)
Diabetes mellitus 16 (8.8) 20 (7.3) 11 (8.1) 9 (6.5)
Smoker 13 (7.2) 12 (4.4) 8 (5.9) 4 (2.9)
Family history of heart disease 99 (54.7) 145 (53.1) 67 (49.6) 78 (56.5)
Personal history cardiovascular
disease*
42 (23.2) 47 (17.2) 22 (16.3) 25(18.1)
Previous single drug treatment 141 (77.9) 173 (63.4) 84 (62.2) 89 (64.5)
Mean (SD) plasma creatinine (ìmol/l) 86.1 (16.9) 88.5 (22.1) 89.4 (21.4) 87.7 (22.8)
Alcohol intake:
Heavy 64 (35.4) 81 (29.7) 41 (30.4) 40 (29.0)
Moderate 83 (45.9) 95 (34.8) 49 (36.3) 46 (33.3)
Never drink 28 (15.5) 78 (28.6) 36 (26.7) 42 (30.4)
Recent exercise 166 (92.7) 236 (90.1) 116 (89.2) 120 (90.9)
*Angina, claudication, stroke, myocardial infarction, coronary artery bypass grafting, or coronary angioplasty.
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cancer and two with vascular events. The remaining
unclassified participant was known to be alive and not
taking antihypertensive drugs at 12 months. In most
instances, drug treatment in “other” participants was
restarted because of ankle swelling (18) or heart failure
(8). Table 1 contrasts the baseline characteristics of the
“maintain normotension” and “return to hyper›
tension” groups, as classified at 12 months after study
entry.
Table 2 shows the results of a multivariate analysis
conducted to determine a set of independent
predictors of maintenance of normotension. These are
expressed as risk ratios, with “return to hypertension”
as the comparison group. In both “return to
hypertension” and “return to hypertension early” lower
on›treatment systolic blood pressure was the major
predictor. Other predictors were younger age (65›74
years), greater waist:hip ratio, and the use of a single
antihypertensive drug.
The figure shows the proportion of the study
population who remained normotensive at various
times after drug withdrawal. It indicates that as many
participants returned to hypertension in the first 70
days as in the subsequent 330 days. The probability of
return to hypertension between 200 days and 400 days
was 0.11.
Discussion
A relatively high percentage (37%) of participants
remained normotensive one year after drug with›
drawal in this study. This finding has been replicated in
other major studies and is similar to the 42% in our
systematic review.1 5 6–13 The figure shows that although
most patients who returned to hypertension did so in
the first 100 days after entry into the study, the rate
thereafter was constant. Thus long term systematic fol›
low up is needed for patients who are offered this strat›
egy in clinical practice.
This study has identified patient characteristics that
predict the likelihood of successful antihypertensive
drug withdrawal among patients treated in a general
practice setting. The patients selected were elderly
(over 65 years) and had blood pressure levels judged to
allow a brief period of safe drug withdrawal before
entry into the second Australian national blood
pressure study. The distribution of blood pressures is
likely to have been similar to that of typical patients
with mild to moderate hypertension encountered in
general practice, which is reflected in the high number
of patients on single drug treatment before drug with›
drawal (table 1).
The study identified several predictors of sustained
normotension as well as early return to hypertension.
All of these were among a series of simple clinical vari›
ables prospectively chosen as likely to be routinely
available to guide a general practitioner’s clinical man›
agement.
Study design
Certain limitations of the study design require
comment. In the first place, the study was largely
observational and relied on judgment by doctors both
for starting antihypertensive treatment and for
determining whether it was appropriate to restart
treatment. Doctors vary in their thresholds for
initiating treatment and are also encouraged to use dif›
ferent thresholds according to the level of integrated
cardiovascular risk in individual patients.14 However, in
all cases return to antihypertensive drug treatment was
initiated by the patients’ general practitioner as “the
most appropriate” course of action for the individual
patient.
Another limitation is the natural variability of
blood pressure and its likelihood of being transiently
elevated—for example, by alcohol intake, other drugs,
or fluctuations in body weight.15 16 Predictors of
successfully sustained normotension may also have a
complex relation to their outcome variable. For exam›
ple, they may reflect factors that have led to more
frequent than normal measurement of blood pressure
or a lower threshold for introduction of treatment
(such as other illnesses or the presence of other cardiac
risk factors); factors that have led to a transient
elevation of blood pressure that has subsequently
resolved or an exaggerated white coat effect (a
transient period of excessive alcohol intake or increase
in body weight); or factors that are associated with
Table 2 Characteristics that are independent predictors of “maintain normotension” status 12 months after withdrawal of all
antihypertensive drugs versus “return to hypertension.” The results for “return to hypertension early” were very similar
Characteristic
Univariate analysis Multivariate analysis
Relative risk (95% CI) P value Relative risk (95% CI) P value
On›treatment systolic blood pressure (10 mm Hg increase) 0.82 (0.75 to 0.89) <0.001 0.85 (0.81 to 0.89) <0.001
Age (years):
65›74 1.61 (1.16 to 2.24) 0.005 1.57 (1.13 to 2.17) 0.007
75›84 1.00 1.00
Waist:hip ratio (0.1 unit increase) 1.12 (0.98 to 1.28) 0.11 1.22 (1.12 to 1.32) 0.02
Single drug treatment 2.44 (1.54 to 3.85) <0.001 2.38 (1.50 to 3.76) <0.001
Two or more drugs 1.00 1.00
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Survival plot of participants’ (n=454) normotensive status over a 12
month period after cessation of antihypertensive treatment.
Participants classified as “other” (n=49) were excluded from this
analysis
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an increased likelihood of success of non›
pharmacological blood pressure reduction.8 13 Alterna›
tively, treatment may have been introduced inappro›
priately because of poor measurement technique, too
few blood pressure measurements, or a failure to initi›
ate behaviour modification before introducing drug
treatment (misclassification error).15 16
Utility of predictors
The predictors identified in this study probably fit into
several of these categories. On›treatment systolic blood
pressure is likely to correlate with the true pretreat›
ment blood pressure and is therefore a plausible
predictor of successful withdrawal. Younger patients
may be more often started on treatment inappropri›
ately because of an exaggerated white coat effect, so
younger age is a plausible predictor of successful with›
drawal. A low waist:hip ratio may predict earlier return
to treatment because doctors have less opportunity to
encourage non›drug treatments (in particular weight
loss), or patients with a higher waist:hip ratio may lose
weight and delay return to hypertension.1 Single drug
treatment reflects the mild nature of the blood
pressure off treatment and is therefore a plausible pre›
dictor.
Considering the strength of the predictors and
their plausible relations to successful antihypertensive
drug withdrawal, it is likely that only a minority of the
candidate predictors will be useful in a clinical setting.
The most relevant predictors of successful withdrawal
are younger age (65›74 years), relatively low
on›treatment systolic pressures, and minimal drug
treatment. Conversely, those least likely to be successful
are older patients with higher on›treatment pressures
and two or more antihypertensive drugs. The
systematic review found that the most consistent
predictors identified among the included studies were
blood pressure (lower pretreatment, on›treatment, and
post›withdrawal), pharmacotherapy (fewer agents and
lower dose), and dietary intervention (weight and
sodium reduction).1
The predictive power of each of the identified
factors was relatively modest, ranging from 0.85 to
2.38. The ability of the model to predict maintenance
of normotension versus return to hypertension was
41% of maintenance of normotension correctly
predicted, 83% of return to hypertension correctly
predicted, and 66% correct overall. The ability of the
model to predict maintenance of normotension versus
“early” return to hypertension was 90% of mainte›
nance of normotension correctly predicted, 38% of
early return to hypertension correctly predicted, and
68% correct overall. Thus identified predictors for
maintenance of normotension are most useful in the
first 70 days after drug withdrawal.
The ability of the model with on›treatment systolic
blood pressure only to predict maintenance of normo›
tension versus return to hypertension was 16% of
maintenance of normotension correctly predicted,
91% of return to hypertension correctly predicted, and
61% correct overall. On›treatment systolic blood pres›
sure is therefore the single most useful measure to
exclude patients from a trial of antihypertensive drug
withdrawal.
However, other more powerful predictors may
exist. Given the wide range of simple measurements in
this study, future studies could test physiological meas›
ures such as arterial compliance and pulse wave veloc›
ity at baseline as clinical tests to predict maintenance of
normotension. Left ventricular hypertrophy, for exam›
ple, has been previously identified as an important
predictor.17
Systematic follow up of all patients offered
withdrawal of antihypertensive drug treatment is man›
datory. As the rate of return to hypertension is greatest
at the time of cessation, a reasonable regimen would be
weekly visits for two weeks, then fortnightly visits for
two months, and then monthly visits for six months.
Beyond this time, six monthly visits should continue
indefinitely. This strategy should be offered only to
patients with uncomplicated hypertension—that is, no
cardiovascular disease or comorbidity for which the
treatment is also needed.
Conclusion
In view of the substantial cost of antihypertensive treat›
ment, the findings of this study emphasise the value of
a trial of withdrawal of antihypertensive treatment with
systematic follow up in patients who fit the profile of
younger (65›74 years) age with blood pressure well
controlled on relatively minimal treatment.
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What is already known on this topic
Systematic reviews have identified predictors of
success of withdrawal of antihypertensive
medication
The reviewed studies have mainly been in a
hospital or specialist clinic setting, and their
recommendations may not be practical in general
practice
What this paper adds
This study has identified simple predictors of
success that are readily available to general
practitioners
On›treatment systolic blood pressure, the number
of blood pressure lowering drugs, and the age of
the patient are reliable indicators of who may
successfully stop taking their drugs
General practitioner practitioners should not be
dissuaded from offering drug withdrawal to
patients with greater waist:hip ratios
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